Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...

The U.S. is having its worst year for measles spread in more than three decades, with a total of 1,288 cases nationally and ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

The dramatic rise of weight-loss drugs such as Ozempic and Mounjaro had upended WeightWatchers' business model ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...